Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MGMT deletion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MGMT promoter methylation (16)

MGMT unmethylation (15)

IDH1 mutation + MGMT promoter methylation (1)

IDH2 mutation + MGMT promoter methylation (1)

SETD2 mutation + MGMT promoter methylation (1)

TERT mutation + MGMT promoter methylation (1)

IDH1 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)

IDH2 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)

MGMT promoter methylation (16)

MGMT unmethylation (15)

IDH1 mutation + MGMT promoter methylation (1)

IDH2 mutation + MGMT promoter methylation (1)

SETD2 mutation + MGMT promoter methylation (1)

TERT mutation + MGMT promoter methylation (1)

IDH1 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)

IDH2 mutation + Chr del(1p) + Chr del(19q) + MGMT promoter methylation (0)

›

MGMT deletion	Neuroendocrine Tumor	MGMT deletion	Neuroendocrine Tumor	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
MGMT deletion	Colorectal Cancer	MGMT deletion	Colorectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MGMT deletion	Neuroendocrine Tumor	MGMT deletion	Neuroendocrine Tumor	temozolomide + capecitabine Sensitive: C3 – Early Trials temozolomide + capecitabine Sensitive : C3	temozolomide + capecitabine Sensitive: C3 – Early Trials temozolomide + capecitabine Sensitive : C3